Advanced Drug Delivery Reviews

Suvoda Introduces Advanced Drug Optimization For IRT to Improve Accuracy of Clinical Trial Drug Supply Management

Retrieved on: 
Thursday, October 12, 2023
Partnership, Central nervous system, Organization, Advanced Drug Delivery Reviews, Carbon, Failure, Buffer, Clinical trial, IRT, CNS, Pharmaceutical industry, Dietary supplement, Fine chemical

PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, announced a new Advanced Drug Optimization feature as part of its latest Interactive Response Technology (IRT) release. This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.

Key Points: 
  • This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.
  • Suvoda introduces Advanced Drug Optimization for IRT to improve accuracy of clinical trial drug supply management.
  • Traditionally, drug supply strategies have relied on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial.
  • And, Advanced Drug Optimization gives us more tools to help our joint customers meet their drug supply needs in ways that better support their clinical trial and organizational goals."

Suvoda Introduces Advanced Drug Optimization For IRT to Improve Accuracy of Clinical Trial Drug Supply Management

Retrieved on: 
Thursday, October 12, 2023
Partnership, Central nervous system, Organization, Advanced Drug Delivery Reviews, Carbon, Failure, Buffer, Clinical trial, IRT, CNS, Pharmaceutical industry, Fine chemical

PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, announced a new Advanced Drug Optimization feature as part of its latest Interactive Response Technology (IRT) release. This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.

Key Points: 
  • This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.
  • Traditionally, drug supply strategies have relied on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial.
  • The Advance Drug Optimization feature aligns with Suvoda's mission to deliver purpose-built e-clinical solutions that give sponsors command over trials with complex drug supply management needs.
  • And, Advanced Drug Optimization gives us more tools to help our joint customers meet their drug supply needs in ways that better support their clinical trial and organizational goals."

DoubleRainbow Biosciences and Kelai Pharmaceuticals to collaborate on novel natural compound therapeutics

Retrieved on: 
Monday, August 22, 2022
Metabolomics, Plant, Synthetic biology, Research, Mental, Therapy, Impact, PMID, Administration, Advanced Drug Delivery Reviews, Psychopharmacology, ADD, Science, Quality of life, Organization, Double, Government budget balance, Double Rainbow, Kavalactone, GLOBE, Medicine, Addiction, Intellectual property, Genomics, Health, Environment, Life, Patient, Fine chemical, Pharmaceutical industry, Medicinal plants, Disease, Piper

Lexington, MA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (Double Rainbow), a sustainable biotech company harnessing bioengineering to improve the quality of human health, announced today a new research collaboration with Kelai Pharmaceuticals (Kelai) to explore the potential of biosynthetic kavalactone therapeutics.

Key Points: 
  • Lexington, MA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (Double Rainbow), a sustainable biotech company harnessing bioengineering to improve the quality of human health, announced today a new research collaboration with Kelai Pharmaceuticals (Kelai) to explore the potential of biosynthetic kavalactone therapeutics.
  • Using Double Rainbows proprietary HARMONYTM platform, the companies will leverage synthetic biology to help Kelai unlock the potential of these natural compounds through sustainable biosynthetic production.
  • As a company, our mission includes doing no harm in the name of doing good, remarks Dr Jacqueline Jacques, Chief Executive Officer of Kelai Pharmaceutical.
  • The supply chain for a natural molecule could be exhausted with the creation of even one new drug.

Predictive Genetic Testing, AI-enabled Drug Discovery, Circular RNA and Advanced Drug Delivery Market 2022: Key Focus is on Precision Oncology Tests for Multiple Therapeutic Applications - ResearchAndMarkets.com

Retrieved on: 
Monday, June 13, 2022
Health, Genetics, Biomarker, Nanomedicine, RNA, Advanced Drug Delivery Reviews, AI, Cancer, Algorithm, Pain, Ministry of Health & Wellness, Therapy, Drug discovery, Genetic engineering, Health, Innovation, Diagnosis, Industry, Wellness, Tissue engineering, Disease management, Drug development, Regenerative medicine, Synthetic biology, ML, Pharmaceutical industry

The "Growth Opportunities in Predictive Genetic Testing, AI-enabled Drug Discovery, Circular RNA, and Advanced Drug Delivery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Predictive Genetic Testing, AI-enabled Drug Discovery, Circular RNA, and Advanced Drug Delivery" report has been added to ResearchAndMarkets.com's offering.
  • The report focuses on technology platforms that leverage AI and ML algorithms for novel target discovery and drug development applications.
  • A key focus of this issue is on precision oncology tests and other predictive genetic tests for multiple therapeutic applications.
  • In addition, advanced drug delivery using engineered cells and biosensors for monitoring therapy efficacy and response have been captured.

Ric Scalzo Institute of Botanical Research and Kelai Pharmaceutical Announce Research Partnership

Retrieved on: 
Tuesday, May 31, 2022
Advanced Drug Delivery Reviews, Knowledge, Canadian College of Naturopathic Medicine, Medicine, Hepatotoxicity, ADD, Botany, Therapy, Nature, Biosafety, Ethanol, Institute, Research, Partnership, SCNM, Intellectual property, Toxicity, Naturopathy, Southwest College of Naturopathic Medicine, Mental health, Outline of health sciences, Brunei Research Department (International), Water, Arizona State University, Pharmaceutical industry

Kava Research Begins at Biosafety Level 2 and Analytical Plant Chemistry Labs

Key Points: 
  • Kelai Pharmaceutical specializes in the development of advanced drug delivery (ADD) technologies that utilize natural compounds to create safer, more effective, and innovative therapies for addiction, mental health disorders, and related conditions
    "We are particularly excited about starting the discovery partnership with the Ric Scalzo Institute for Botanical Research that builds on a rich traditional use of Kava.
  • We see this as the platform for accelerating our forward-looking research and discoveries around Kava," said Jacqueline Jacques, ND, Chief Executive Officer, Kelai Pharmaceutical.
  • When considering botanical material for research, the team analyzes the plant's background, supply chain, ethnobotanical history, and relevant clinical data.
  • For more information on the Ric Scalzo Institute for Botanical Research, visit scnm.edu/research.

Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews

Retrieved on: 
Monday, October 11, 2021
NASDAQ, Private Securities Litigation Reform Act, Company, Forward-looking statement, Brain, Patent, Technology, COVID-19, Infection, Risk, Ovarian cancer, National, High-intensity focused ultrasound, Duke Cancer Institute, Heat, University Medical Center Utrecht, Phase, Breast cancer, Radiation therapy, Duke University School of Medicine, Development, GLOBE, Time, Failure, Safety, Cooperative research and development agreement, Thermoregulation, Doctor of Philosophy, Doxorubicin, CRADA, FDA, Hyperthermia, News, U.S. Securities and Exchange Commission, Advanced Drug Delivery Reviews, Gustavo, University of Oxford, Immunotherapy, Cancer, Security (finance), High, HIFU, Severe acute respiratory syndrome coronavirus 2, NIH, Â, Patient, Research, Pancreatic cancer, Science, Pharmaceutical industry, Medical imaging

ZUG, Switzerland, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Celsion GmbH, a wholly owned subsidiary of Celsion Corporation (NASDAQ: CLSN), a clinical-stage biotechnology company focused on DNA-based immunotherapy and next-generation vaccines, announces the journal Advanced Drug Delivery Reviews has published an article reviewing the history of ThermoDox®, from animal studies through to the Phase III OPTIMA Study in advanced liver cancer. Titled “Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery,” the article was authored by Nicholas Borys, M.D., Executive Vice President and Chief Medical Officer of Celsion, and Mark W. Dewhirst, D.V.M., Ph.D., the Gustavo S. Montana Professor of Radiation Oncology and Vice Director for Basic Science of the Duke Cancer Institute at Duke University School of Medicine, and is available [here/link].

Key Points: 
  • The articles authors noted that ThermoDox is the first heat-activated formulation of a liposomal drug carrier to be utilized in human clinical trials.
  • According to Dr. Borys, As our recent paper in Advanced Drug Delivery Reviews points out there was much learned regarding the application of ThermoDox with heat technology.
  • The collaboration between the NIH and Celsion on ThermoDox is an exciting step toward better therapies for patients with cancer.
  • Andreas Voss, M.D., Managing Director of Celsion GmbH, added, This publication provides a comprehensive summary of the development of ThermoDox to date.